​

Elevance Health (ELV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ELV Stock Forecast

Elevance Health (ELV) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $525.33, with a high of $625.00 and a low of $478.00. This represents a 31.23% increase from the last price of $400.30.

$350 $410 $470 $530 $590 $650 High: $625 Avg: $525.33 Low: $478 Last Closed Price: $400.3

ELV Stock Rating

Elevance Health stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (92.31%), 1 Hold (7.69%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 12 0 Strong Sell Sell Hold Buy Strong Buy

ELV Forecast vs Benchmarks

TypeNameUpside
StockElevance Health31.23%
SectorHealthcare Stocks 25.20%
IndustryHealthcare Plans Stocks17.36%

Price Target Trends

1M3M12M
# Anlaysts--15
Avg Price Target--$576.93
Last Closing Price$400.30$400.30$400.30
Upside/Downside--44.12%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 255145--24
Dec, 246144--24
Nov, 247134--24
Oct, 247144--25
Sep, 247144--25
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2024David WindleyJefferies$529.00$430.7722.80%32.15%
Oct 21, 2024Whit MayoLeerink Partners$515.00$430.7719.55%28.65%
Oct 18, 2024Sarah JamesRaymond James$485.00$432.5312.13%21.16%
Oct 18, 2024Ben HendrixRBC Capital$478.00$444.357.57%19.41%
Oct 18, 2024David MacDonaldTruist Financial$520.00$444.3517.02%29.90%
Oct 16, 2024Michael HaRobert W. Baird$625.00$483.8729.17%56.13%
Jul 18, 2024Ben HendrixRBC Capital$585.00$502.0616.52%46.14%
Jul 15, 2024David MacDonaldTruist Financial$620.00$535.5415.77%54.88%
Jun 24, 2024Erin WrightMorgan Stanley$643.00$534.4220.32%60.63%
May 29, 2024Michael HaRobert W. Baird$649.00$505.5228.38%62.13%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2024Cowen & Co.BuyBuyhold
Oct 21, 2024JefferiesBuyBuyhold
Oct 21, 2024Leerink PartnersOutperformOutperformhold
Oct 18, 2024UBSBuyBuyhold
Oct 18, 2024Wells FargoBuyBuyhold
Oct 18, 2024RBC CapitalOutperformOutperformhold
Oct 10, 2024BarclaysOverweightOverweighthold
Aug 19, 2024Wells FargoBuyBuyhold
Jul 19, 2024Cowen & Co.BuyBuyhold
Jul 18, 2024BarclaysOverweightOverweighthold

Financial Forecast

EPS Forecast

$15 $25 $35 $45 $55 $65 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$18.23$25.04$24.56$25.69------
Avg Forecast$22.42$25.94$29.02$33.07$33.21$34.49$39.12$45.09$53.01$60.81
High Forecast$21.54$24.92$27.99$33.01$32.43$31.08$34.75$42.00$50.33$57.73
Low Forecast$23.15$26.78$29.93$33.17$33.39$35.31$43.70$46.79$55.16$63.27
Surprise %-18.69%-3.47%-15.37%-22.32%------

Revenue Forecast

$100B $140B $180B $220B $260B $300B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$121.87B$138.64B$156.59B$171.34B------
Avg Forecast$120.37B$137.85B$156.30B$170.38B$175.83B$191.75B$205.47B$221.23B$241.40B$279.48B
High Forecast$116.70B$133.66B$152.01B$169.32B$174.23B$183.87B$194.40B$220.09B$232.01B$268.60B
Low Forecast$123.37B$141.29B$160.07B$171.02B$177.24B$196.06B$217.15B$222.36B$248.91B$288.17B
Surprise %1.25%0.57%0.19%0.56%------

Net Income Forecast

$0 $3B $6B $9B $12B $15B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$4.57B$6.10B$5.89B$5.99B------
Avg Forecast$4.48B$5.67B$6.08B$5.99B$7.67B$7.74B$9.14B$10.35B$12.36B$14.17B
High Forecast$3.59B$4.54B$4.87B$4.79B$7.56B$7.24B$8.10B$9.79B$11.73B$13.46B
Low Forecast$5.38B$6.81B$7.30B$7.18B$7.78B$8.23B$10.19B$10.91B$12.86B$14.75B
Surprise %1.99%7.56%-3.08%-------

ELV Forecast FAQ

Is Elevance Health stock a buy?

Elevance Health stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Elevance Health is a favorable investment for most analysts.

What is Elevance Health's price target?

Elevance Health's price target, set by 13 Wall Street analysts, averages $525.33 over the next 12 months. The price target range spans from $478 at the low end to $625 at the high end, suggesting a potential 31.23% change from the previous close price of $400.3.

How does Elevance Health stock forecast compare to the average forecast of its sector, industry, and investment themes?

Elevance Health stock forecast shows a 31.23% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the healthcare plans stocks industry (17.36%).

What is the breakdown of analyst ratings for Elevance Health over the past three months?

  • January 2025: 20.83% Strong Buy, 58.33% Buy, 20.83% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 25.00% Strong Buy, 58.33% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 29.17% Strong Buy, 54.17% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Elevance Health’s EPS forecast?

Elevance Health's average annual EPS forecast for its fiscal year ending in December is 33.21 for 2024, a 29.27% increase from the reported $25.69 in 2023. The prediction for 2025 is $34.49, $39.12 for 2026, $45.09 for 2027, $53.01 for 2028, and $60.81 for 2029.

What is Elevance Health’s revenue forecast?

Elevance Health's average annual revenue forecast for its fiscal year ending in December is $175.83B for 2024, a 2.62% increase from the reported $171.34B in 2023. The forecast for 2025 is $191.75B, $205.47B for 2026, $221.23B for 2027, $241.4B for 2028, and $279.48B for 2029.

What is Elevance Health’s net income forecast?

For its fiscal year ending in December, Elevance Health's average annual net income forecast is $7.67B for 2024, reflecting an 28.14% increase from the reported $5.99B in 2023. The projection for 2025 is $7.74B, $9.14B for 2026, $10.35B for 2027, $12.36B for 2028, and $14.17B for 2029.